Similarly, Eckardt et al. [23] observed no significant impact of secondary-type mutations on patient outcomes (CR, EFS and OS) for patients with NPM1-mutated AML, despite the fact that patients without secondary-type mutations were younger, with a higher proportion proceeding to allo-SCT. Here, NPM1 is linked to acute myeloid leukemia.